Trial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option Anti-EphA2 CAR-T therapy appears to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results